Pharmacophore-Guided Generative Design of Novel Drug-Like Molecules

• URL: http://arxiv.org/abs/2510.01480v1
• Date: Wed, 01 Oct 2025 21:45:58 GMT
• Title: Pharmacophore-Guided Generative Design of Novel Drug-Like Molecules
• Authors: Ekaterina Podplutova, Anastasia Vepreva, Olga A. Konovalova, Vladimir Vinogradov, Dmitrii O. Shkil, Andrei Dmitrenko,
• Abstract summary: We present a novel generative framework that balances pharmacophore similarity to reference compounds with structural diversity from active molecules.<n>We demonstrate its applicability through a case study targeting estrogen receptor modulators and antagonists for breast cancer.
• Score: 1.8472148461613156
• License: http://creativecommons.org/licenses/by/4.0/
• Abstract: The integration of artificial intelligence (AI) in early-stage drug discovery offers unprecedented opportunities for exploring chemical space and accelerating hit-to-lead optimization. However, docking optimization in generative approaches is computationally expensive and may lead to inaccurate results. Here, we present a novel generative framework that balances pharmacophore similarity to reference compounds with structural diversity from active molecules. The framework allows users to provide custom reference sets, including FDA-approved drugs or clinical candidates, and guides the \textit{de novo} generation of potential therapeutics. We demonstrate its applicability through a case study targeting estrogen receptor modulators and antagonists for breast cancer. The generated compounds maintain high pharmacophoric fidelity to known active molecules while introducing substantial structural novelty, suggesting strong potential for functional innovation and patentability. Comprehensive evaluation of the generated molecules against common drug-like properties confirms the robustness and pharmaceutical relevance of the approach.

Related papers

• ReACT-Drug: Reaction-Template Guided Reinforcement Learning for de novo Drug Design [0.34155322317700576]
  We introduce bfReACT-Drug, a fully integrated, target-agnostic molecular design framework based on Reinforcement Learning.<n>This architecture highlights the potential of integrating structural biology, deep representation learning, and chemical rules to automate and accelerate rational drug design.
  arXiv  Detail & Related papers  (2025-12-24T05:29:35Z)
• QCA-MolGAN: Quantum Circuit Associative Molecular GAN with Multi-Agent Reinforcement Learning [2.2463678997251604]
  This work presents a novel quantum circuit Born machine (QCBM)-enabled Generative Adrialversa Network (GAN), called QCA-MolGAN, for generating drug-like molecules.<n>QCBM serves as a learnable prior distribution, which is associatively trained to define a latent space aligning with high-level features captured by the GANs discriminator.<n>We integrate a novel multi-agent reinforcement learning network to guide molecular generation with desired targeted properties.
  arXiv  Detail & Related papers  (2025-09-05T12:31:58Z)
• Pharmacophore-Conditioned Diffusion Model for Ligand-Based De Novo Drug Design [0.0]
  We present PharmaDiff, a pharmacophore-conditioned diffusion model for 3D molecular generation.<n>PharmaDiff employs a transformer-based architecture to integrate an atom-based representation of the 3D pharmacophore into the generative process.
  arXiv  Detail & Related papers  (2025-05-15T17:54:29Z)
• DrugGen: Advancing Drug Discovery with Large Language Models and Reinforcement Learning Feedback [0.0]
  DrugGen is an enhanced model based on the DrugGPT structure. It is fine-tuned on approved drug-target interactions and optimized with proximal policy optimization. By producing high-quality small molecules, DrugGen provides a high-performance medium for advancing pharmaceutical research and drug discovery.
  arXiv  Detail & Related papers  (2024-11-20T01:21:07Z)
• Aligning Target-Aware Molecule Diffusion Models with Exact Energy Optimization [147.7899503829411]
  AliDiff is a novel framework to align pretrained target diffusion models with preferred functional properties. It can generate molecules with state-of-the-art binding energies with up to -7.07 Avg. Vina Score.
  arXiv  Detail & Related papers  (2024-07-01T06:10:29Z)
• DecompOpt: Controllable and Decomposed Diffusion Models for Structure-based Molecular Optimization [49.85944390503957]
  DecompOpt is a structure-based molecular optimization method based on a controllable and diffusion model. We show that DecompOpt can efficiently generate molecules with improved properties than strong de novo baselines.
  arXiv  Detail & Related papers  (2024-03-07T02:53:40Z)
• Mitigating Molecular Aggregation in Drug Discovery with Predictive Insights from Explainable AI [0.5242869847419834]
  We present the application of MEGAN, our explainable AI (xAI) model, for the identification of small colloidally aggregating molecules (SCAMs)<n>This work offers solutions to the long-standing problem of false positives caused by SCAMs in high throughput screening for drug discovery.
  arXiv  Detail & Related papers  (2023-06-03T22:30:45Z)
• Tailoring Molecules for Protein Pockets: a Transformer-based Generative Solution for Structured-based Drug Design [133.1268990638971]
  De novo drug design based on the structure of a target protein can provide novel drug candidates. We present a generative solution named TamGent that can directly generate candidate drugs from scratch for a given target.
  arXiv  Detail & Related papers  (2022-08-30T09:32:39Z)
• Retrieval-based Controllable Molecule Generation [63.44583084888342]
  We propose a new retrieval-based framework for controllable molecule generation. We use a small set of molecules to steer the pre-trained generative model towards synthesizing molecules that satisfy the given design criteria. Our approach is agnostic to the choice of generative models and requires no task-specific fine-tuning.
  arXiv  Detail & Related papers  (2022-08-23T17:01:16Z)
• Learning To Navigate The Synthetically Accessible Chemical Space Using Reinforcement Learning [75.95376096628135]
  We propose a novel forward synthesis framework powered by reinforcement learning (RL) for de novo drug design. In this setup, the agent learns to navigate through the immense synthetically accessible chemical space. We describe how the end-to-end training in this study represents an important paradigm in radically expanding the synthesizable chemical space.
  arXiv  Detail & Related papers  (2020-04-26T21:40:03Z)
• CogMol: Target-Specific and Selective Drug Design for COVID-19 Using Deep Generative Models [74.58583689523999]
  We propose an end-to-end framework, named CogMol, for designing new drug-like small molecules targeting novel viral proteins. CogMol combines adaptive pre-training of a molecular SMILES Variational Autoencoder (VAE) and an efficient multi-attribute controlled sampling scheme. CogMol handles multi-constraint design of synthesizable, low-toxic, drug-like molecules with high target specificity and selectivity.
  arXiv  Detail & Related papers  (2020-04-02T18:17:20Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.